A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Akeso
- Target Recruit Count
- 60
- Registration Number
- NCT05432492
A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Akeso
- Target Recruit Count
- 36
- Registration Number
- NCT05393063
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Akeso
- Target Recruit Count
- 254
- Registration Number
- NCT05382442
- Locations
- 🇺🇸
Summit Therapeutics Research Site, Los Angeles, California, United States
🇨🇳The Sixth Hospital,Sun Yat-sen University, Guanzhou, Guangdong, China
A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
Phase 2
Active, not recruiting
- Conditions
- Unresectable, Non-metastatic Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Akeso
- Target Recruit Count
- 60
- Registration Number
- NCT05319431
- Locations
- 🇨🇳
The First Hospital of Beijing University, Beijing, Beijing, China
🇨🇳Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
A Clinical Study of AK115 in Healthy Subjects
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Akeso
- Target Recruit Count
- 42
- Registration Number
- NCT05286970
- Locations
- 🇨🇳
Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming, Yunnan, China
A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Akeso
- Target Recruit Count
- 246
- Registration Number
- NCT05260411
- Locations
- 🇨🇳
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Zhongshan Hospital, Fudan Hospital, Shanghai, China
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Renal Cell CarcinomaFirst-line Treatment
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Akeso
- Target Recruit Count
- 70
- Registration Number
- NCT05256472
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Akeso
- Target Recruit Count
- 464
- Registration Number
- NCT05255094
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Akeso
- Target Recruit Count
- 122
- Registration Number
- NCT05255458
- Locations
- 🇨🇳
The Third Hospital of Nanchang, Nanchang, Jiangxi, China
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
Phase 2
Not yet recruiting
- Conditions
- Resectable Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2022-02-21
- Lead Sponsor
- Akeso
- Target Recruit Count
- 30
- Registration Number
- NCT05247684
© Copyright 2025. All Rights Reserved by MedPath